Current perspective: Bevacizumab in colorectal cancer – A time for reappraisal?
- 30 September 2009
- journal article
- research article
- Published by Elsevier in European Journal Of Cancer
- Vol. 45 (14) , 2452-2461
- https://doi.org/10.1016/j.ejca.2009.06.028
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon CancerJournal of Clinical Oncology, 2009
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal CancerNew England Journal of Medicine, 2009
- Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal CancerNew England Journal of Medicine, 2009
- Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)Journal of Clinical Oncology, 2008
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III StudyJournal of Clinical Oncology, 2008
- Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforationInvestigational New Drugs, 2008
- Safe liver resection following chemotherapy for colorectal metastases is a matter of timingBritish Journal of Cancer, 2007
- Combined Analysis of Efficacy: The Addition of Bevacizumab to Fluorouracil/Leucovorin Improves Survival for Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2005
- Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and AngiogenesisJournal of Clinical Oncology, 2005
- A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal CancerJournal of Clinical Oncology, 2004